Momenta Wins Dismissal Of Blood-Clot Drug Antitrust Suit
Law360, Los Angeles (July 27, 2016, 9:43 PM EDT) -- A Massachusetts federal judge on Wednesday said that Amphastar Pharmaceuticals Inc. cannot bring federal antitrust claims against Momenta Pharmaceuticals Inc. for allegedly suppressing competition of sales of a generic blood clot drug because its alleged injury stems from a prior court-issued injunction, immunizing Momenta from suit.
Momenta and co-defendant Sandoz Inc., which together develop and manufacture enoxaparin — a generic life-saving anti-coagulant drug used in clinical settings to treat blood clots that is sold under the brand name Lovenox — are immunized from Amphastar’s antitrust claims by the so-called Noerr-Pennington doctrine, since a federal court had once enjoined Amphastar from launching...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!